Norway
· Delayed Price · Currency is NOK Ultimovacs ASA Statistics
Total Valuation
Ultimovacs ASA has a market cap or net worth of NOK 75.69 million. The enterprise value is -52.75 million.
| Market Cap | 75.69M |
| Enterprise Value | -52.75M |
Important Dates
The last earnings date was Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Ultimovacs ASA has 34.41 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 34.41M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 15.96% |
| Float | 23.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.40 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.35 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.29 |
Financial Position
The company has a current ratio of 11.36, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.36 |
| Quick Ratio | 11.29 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -104.74 |
Financial Efficiency
Return on equity (ROE) is -57.48% and return on invested capital (ROIC) is -38.57%.
| Return on Equity (ROE) | -57.48% |
| Return on Assets (ROA) | -33.62% |
| Return on Capital (ROIC) | -38.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -8.78M |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.08% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -98.08% |
| 50-Day Moving Average | 1.80 |
| 200-Day Moving Average | 19.25 |
| Relative Strength Index (RSI) | 62.41 |
| Average Volume (20 Days) | 299,528 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -162.35M |
| Pretax Income | -149.28M |
| Net Income | -149.28M |
| EBITDA | -161.44M |
| EBIT | -162.35M |
| Earnings Per Share (EPS) | -4.34 |
Balance Sheet
The company has 131.00 million in cash and 2.55 million in debt, giving a net cash position of 128.45 million or 3.73 per share.
| Cash & Cash Equivalents | 131.00M |
| Total Debt | 2.55M |
| Net Cash | 128.45M |
| Net Cash Per Share | 3.73 |
| Equity (Book Value) | 191.01M |
| Book Value Per Share | 5.55 |
| Working Capital | 127.74M |
Cash Flow
In the last 12 months, operating cash flow was -181.12 million and capital expenditures -17,000, giving a free cash flow of -181.14 million.
| Operating Cash Flow | -181.12M |
| Capital Expenditures | -17,000 |
| Free Cash Flow | -181.14M |
| FCF Per Share | -5.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ultimovacs ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | -197.21% |
| FCF Yield | -239.30% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |